Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis-Reference-Cited by-同舟云学术

Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis

Published:2019-08-06 Issue:11 Volume:39 Page:2052-2060
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Crossan Catriona¹,Majumdar Avik²,Srivastava Ankur²^ORCID,Thorburn Douglas²,Rosenberg William²,Pinzani Massimo²,Longworth Louise¹³,Tsochatzis Emmanuel A.²^ORCID

Affiliation:

1. Health Economics Research Group Brunel University London UK

2. UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free Hospital and UCL London UK

3. PHMR Limited London UK

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14198

Reference29 articles.

1. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort

2. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

3. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

4. Long-term follow-up of patients with NAFLD and elevated liver enzymes

5. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis;Scientific Reports;2024-09-05

2. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies;Chinese Journal of Natural Medicines;2024-08

3. Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population;2024-07-22

4. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis;World Journal of Gastroenterology;2024-05-14

5. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms;Journal of Hepatology;2024-05